

Melanie Janning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5569880/publications.pdf>

Version: 2024-02-01

31
papers

758
citations

687363

13
h-index

526287

27
g-index

31
all docs

31
docs citations

31
times ranked

1670
citing authors

#	ARTICLE	IF	CITATIONS
1	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. <i>Blood</i> , 2013, 122, 2443-2452.	1.4	178
2	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019, 11, 835.	3.7	109
3	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating <i>FLT3</i> mutations. <i>British Journal of Haematology</i> , 2015, 169, 694-700.	2.5	90
4	Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 1184.	4.8	65
5	Anti-Angiogenics: Their Value in Lung Cancer Therapy. <i>Oncology Research and Treatment</i> , 2018, 41, 172-180.	1.2	34
6	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). <i>Oncoimmunology</i> , 2020, 9, 1738798.	4.6	34
7	Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3). <i>Journal of Biological Chemistry</i> , 2015, 290, 25275-25292.	3.4	33
8	Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. <i>Oncotarget</i> , 2015, 6, 6341-6358.	1.8	28
9	Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients. <i>Cancers</i> , 2020, 12, 442.	3.7	28
10	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6993.	4.1	26
11	Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. <i>Future Oncology</i> , 2014, 10, 1157-1165.	2.4	22
12	Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?. <i>Expert Review of Hematology</i> , 2015, 8, 135-138.	2.2	21
13	Identification of a High-Level MET Amplification in CTCs and cTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e243-e246.	1.1	18
14	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e169-e173.	2.5	14
15	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. <i>Cells</i> , 2020, 9, 2337.	4.1	13
16	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	5.1	12
17	Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis. <i>Cancers</i> , 2020, 12, 1166.	3.7	10
18	Acute Megakaryoblastic Leukemia in a Patient with Xeroderma Pigmentosum: Discussion of Pathophysiological, Prognostic, and Toxicological Aspects. <i>Acta Haematologica</i> , 2013, 129, 121-125.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS. <i>Blood</i> , 2018, 132, 2672-2672.	1.4	5
20	Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery. <i>Lung Cancer</i> , 2022, 164, 46-51.	2.0	3
21	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSC 17-10 CIARA trial). <i>British Journal of Haematology</i> , 2018, 183, 235-241.	2.5	2
22	Abstract 2219: Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma of the bladder. , 2019, , .		1
23	BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles. <i>Blood</i> , 2016, 128, 592-592.	1.4	1
24	Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmacodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7020-7020.	1.6	1
25	The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.. <i>Journal of Clinical Oncology</i> , 2018, 36, 70-70.	1.6	1
26	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	1.4	1
27	Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11522-11522.	1.6	1
28	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. <i>Cancer Research</i> , 2022, 82, 3374-3374.	0.9	1
29	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSC 17-10) Tj ETQq1 1 0.784314 rgBT /Overl		
30	Abstract 5581: Clinical validation of a highly sensitive assay to detect mutations in plasma from advanced lung adenocarcinoma patients. , 2018, , .		0
31	Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma. <i>Biomarkers in Medicine</i> , 2020, 14, 1651-1662.	1.4	0